Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma

J. J. Costanzi, M. R. Cooper, J. H. Scarffe, H. Ozer, S. S. Grubbs, R. W. Ferraresi, Richard B Pollard, R. J. Spiegel

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

A multicenter phase II study of INTRON, recombinant alpha-2 interferon (Schering Corp, Kenilworth, NJ), in patients with relapsing or refractory myeloma was initiated. Patients received either intravenous therapy for two weeks followed by subcutaneous therapy or subcutaneous dosing from initiation of treatment. Of 38 evaluable patients, 19 were refractory and 19 had relapses at entry. Twenty-five of 38 had received prior treatment with multiple drugs. Responses were seen among 2/19 refractory patients and 5/19 relapsing patients. Three of seven responders continue to respond for more than one year while receiving maintenance therapy. Most patients experienced improvement in bone pain, and one patient, with a complete response, had healing of bone lesions. Survival curves show a statistically significant improvement in survival for responders v nonresponders. INTRON was well-tolerated with only four patients discontinuing treatment due to adverse effects. Thirty-two percent of patients had hematologic toxicity requiring dose adjustment; however, there was no evidence of cumulative hematologic toxicity. No patients developed serum neutralizing factors to interferon. Additional trials are warranted to study the activity of INTRON in previously untreated patients.

Original languageEnglish (US)
Pages (from-to)654-659
Number of pages6
JournalJournal of Clinical Oncology
Volume3
Issue number5
StatePublished - 1985
Externally publishedYes

Fingerprint

Multiple Myeloma
Interferon-alpha
Therapeutics
Social Adjustment
Bone and Bones
Survival
Interferons
Recurrence
Pain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Costanzi, J. J., Cooper, M. R., Scarffe, J. H., Ozer, H., Grubbs, S. S., Ferraresi, R. W., ... Spiegel, R. J. (1985). Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. Journal of Clinical Oncology, 3(5), 654-659.

Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. / Costanzi, J. J.; Cooper, M. R.; Scarffe, J. H.; Ozer, H.; Grubbs, S. S.; Ferraresi, R. W.; Pollard, Richard B; Spiegel, R. J.

In: Journal of Clinical Oncology, Vol. 3, No. 5, 1985, p. 654-659.

Research output: Contribution to journalArticle

Costanzi, JJ, Cooper, MR, Scarffe, JH, Ozer, H, Grubbs, SS, Ferraresi, RW, Pollard, RB & Spiegel, RJ 1985, 'Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma', Journal of Clinical Oncology, vol. 3, no. 5, pp. 654-659.
Costanzi JJ, Cooper MR, Scarffe JH, Ozer H, Grubbs SS, Ferraresi RW et al. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. Journal of Clinical Oncology. 1985;3(5):654-659.
Costanzi, J. J. ; Cooper, M. R. ; Scarffe, J. H. ; Ozer, H. ; Grubbs, S. S. ; Ferraresi, R. W. ; Pollard, Richard B ; Spiegel, R. J. / Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. In: Journal of Clinical Oncology. 1985 ; Vol. 3, No. 5. pp. 654-659.
@article{77641824810e49cfa3242605faa57a9e,
title = "Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma",
abstract = "A multicenter phase II study of INTRON, recombinant alpha-2 interferon (Schering Corp, Kenilworth, NJ), in patients with relapsing or refractory myeloma was initiated. Patients received either intravenous therapy for two weeks followed by subcutaneous therapy or subcutaneous dosing from initiation of treatment. Of 38 evaluable patients, 19 were refractory and 19 had relapses at entry. Twenty-five of 38 had received prior treatment with multiple drugs. Responses were seen among 2/19 refractory patients and 5/19 relapsing patients. Three of seven responders continue to respond for more than one year while receiving maintenance therapy. Most patients experienced improvement in bone pain, and one patient, with a complete response, had healing of bone lesions. Survival curves show a statistically significant improvement in survival for responders v nonresponders. INTRON was well-tolerated with only four patients discontinuing treatment due to adverse effects. Thirty-two percent of patients had hematologic toxicity requiring dose adjustment; however, there was no evidence of cumulative hematologic toxicity. No patients developed serum neutralizing factors to interferon. Additional trials are warranted to study the activity of INTRON in previously untreated patients.",
author = "Costanzi, {J. J.} and Cooper, {M. R.} and Scarffe, {J. H.} and H. Ozer and Grubbs, {S. S.} and Ferraresi, {R. W.} and Pollard, {Richard B} and Spiegel, {R. J.}",
year = "1985",
language = "English (US)",
volume = "3",
pages = "654--659",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma

AU - Costanzi, J. J.

AU - Cooper, M. R.

AU - Scarffe, J. H.

AU - Ozer, H.

AU - Grubbs, S. S.

AU - Ferraresi, R. W.

AU - Pollard, Richard B

AU - Spiegel, R. J.

PY - 1985

Y1 - 1985

N2 - A multicenter phase II study of INTRON, recombinant alpha-2 interferon (Schering Corp, Kenilworth, NJ), in patients with relapsing or refractory myeloma was initiated. Patients received either intravenous therapy for two weeks followed by subcutaneous therapy or subcutaneous dosing from initiation of treatment. Of 38 evaluable patients, 19 were refractory and 19 had relapses at entry. Twenty-five of 38 had received prior treatment with multiple drugs. Responses were seen among 2/19 refractory patients and 5/19 relapsing patients. Three of seven responders continue to respond for more than one year while receiving maintenance therapy. Most patients experienced improvement in bone pain, and one patient, with a complete response, had healing of bone lesions. Survival curves show a statistically significant improvement in survival for responders v nonresponders. INTRON was well-tolerated with only four patients discontinuing treatment due to adverse effects. Thirty-two percent of patients had hematologic toxicity requiring dose adjustment; however, there was no evidence of cumulative hematologic toxicity. No patients developed serum neutralizing factors to interferon. Additional trials are warranted to study the activity of INTRON in previously untreated patients.

AB - A multicenter phase II study of INTRON, recombinant alpha-2 interferon (Schering Corp, Kenilworth, NJ), in patients with relapsing or refractory myeloma was initiated. Patients received either intravenous therapy for two weeks followed by subcutaneous therapy or subcutaneous dosing from initiation of treatment. Of 38 evaluable patients, 19 were refractory and 19 had relapses at entry. Twenty-five of 38 had received prior treatment with multiple drugs. Responses were seen among 2/19 refractory patients and 5/19 relapsing patients. Three of seven responders continue to respond for more than one year while receiving maintenance therapy. Most patients experienced improvement in bone pain, and one patient, with a complete response, had healing of bone lesions. Survival curves show a statistically significant improvement in survival for responders v nonresponders. INTRON was well-tolerated with only four patients discontinuing treatment due to adverse effects. Thirty-two percent of patients had hematologic toxicity requiring dose adjustment; however, there was no evidence of cumulative hematologic toxicity. No patients developed serum neutralizing factors to interferon. Additional trials are warranted to study the activity of INTRON in previously untreated patients.

UR - http://www.scopus.com/inward/record.url?scp=0021912498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021912498&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 654

EP - 659

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -